Altered mRNA expression of hepatic lipogenic enzyme and PPARalpha in rats fed dietary levan from Zymomonas mobilis.
Levan or high molecular beta-2,6-linked fructose polymer is produced extracellularly from sucrose-based substrates by bacterial levansucrase. In the present study, to investigate the effect of levan feeding on serum leptin, hepatic lipogenic enzyme and peroxisome proliferation-activated receptor (PPAR) alpha expression in high-fat diet-induced obese rats, 4-week-old Sprague-Dawley male rats were fed high-fat diet (beef tallow, 40% of calories as fat), and, 6 weeks later, the rats were fed 0%, 1%, 5% or 10% levan-supplemented diets for 4 weeks. Serum leptin and insulin level were dose dependently reduced in levan-supplemented diet-fed rats. The mRNA expressions of hepatic fatty acid synthase and acetyl CoA carboxylase, which are the key enzymes in fatty acid synthesis, were down-regulated by dietary levan. However, dietary levan did not affect the gene expression of hepatic malic enzyme, phosphatidate phosphohydrolase and HMG CoA reductase. Also, the lipogenic enzyme gene expression in the white adipose tissue (WAT) was not affected by the diet treatments. However, hepatic PPARalpha mRNA expression was dose dependently up-regulated by dietary levan, whereas PPARgamma in the WAT was not changed. The results suggest that the in vivo hypolipidemic effect of dietary levan, including anti-obesity and lipid-lowering, may result from the inhibition of lipogenesis and stimulation of lipolysis, accompanied with regulation of hepatic lipogenic enzyme and PPARalpha gene expression.
Kang
Soon Ah
SA
Department of Molecular Biotechnology, Bio/Molecular Informatics Center, Konkuk University, Seoul 143-701, South Korea.
Hong
Kyunghee
K
Jang
Ki-Hyo
KH
Kim
Yun-Young
YY
Choue
Ryowon
R
Lim
Yoongho
Y
D000103:Acetyl-CoA Carboxylase / Q000235:genetics; D000273:Adipose Tissue / Q000201:enzymology; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage; D004032:Diet; D002149:Energy Intake; D004734:Energy Metabolism; D064429:Fatty Acid Synthases / Q000235:genetics; D005227:Fatty Acids / Q000096:biosynthesis; D005630:Fructans / Q000008:administration & dosage*; D005786:Gene Expression Regulation / Q000187:drug effects; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000096:biosynthesis*; D008099:Liver / Q000201:enzymology*; D008297:Male; D047493:PPAR alpha / Q000235:genetics*; D012333:RNA, Messenger / Q000032:analysis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017355:Zymomonas / Q000737:chemistry*
D019440:Anti-Obesity Agents; D005227:Fatty Acids; D005630:Fructans; D000960:Hypolipidemic Agents; D007328:Insulin; D020738:Leptin; D008055:Lipids; D047493:PPAR alpha; D012333:RNA, Messenger; C072599:levan; D064429:Fatty Acid Synthases; D000103:Acetyl-CoA Carboxylase